CEL-SCI Asks FDA to Lift Partial Clinical Hold on Multikine for Head and Neck Cancers
News
CEL-SCI’s Phase 3 clinical trial assessing its investigational drug Multikine in patients with squamous cell carcinoma of the head and neck (SCCHN) recently was placed on partial clinical hold by ... Read more